01—Abstract
Summary
Summary of the 8-K filed September 22, 2026. Cited figures are marked; the original filing is the authoritative source.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) filed a Form 8-K on September 22, 2026 to disclose the appointment of Pascal Desroches to its Board of Directors, effective January 4, 2027.
Desroches is currently Senior Executive Vice President and Chief Financial Officer of AT&T, and he is slated to retire from AT&T on December 31, 2026. The Board also named him to the Audit Committee and the Talent, Culture, and Compensation Committee, effective the same date. The filing is governance-focused and contains no financial results, guidance, or material transactions.
For investors, the key takeaway is the addition of a seasoned finance executive with deep capital-allocation, investor-relations, and audit experience. His background includes CFO roles at WarnerMedia and Turner Broadcasting, earlier work at KPMG and the SEC, and current audit committee chairmanship at Honeywell Aerospace. He also has prior healthcare governance experience through about four years on the DaVita board.
His placement on the Audit Committee is particularly relevant given his regulatory and accounting background, and his committee assignments suggest the Board values financial oversight and compensation governance. The filing states that Desroches will receive standard non-employee director compensation under the company's program described in its March 19, 2026 proxy statement, and that GE HealthCare will enter into an indemnification agreement with him.
The filing also reports no arrangement or understanding with any other person regarding his selection, and no related-party transactions requiring disclosure under Item 404(a). The appointment is a routine but noteworthy board refresh with no immediate financial impact.
02—Key points
Key Highlights
- Board appointment: Pascal Desroches, current AT&T SEVP and CFO, appointed to GEHC's Board effective January 4, 2027.
- Committee roles: Named to both the Audit Committee and the Talent, Culture, and Compensation Committee, effective the same date.
- Retirement timing: Desroches plans to retire from AT&T on December 31, 2026, which aligns with his January 2027 board start date.
- Finance credentials: Prior CFO experience at WarnerMedia and Turner Broadcasting, plus earlier roles at KPMG and the SEC, and current audit chair role at Honeywell Aerospace.
- Healthcare governance experience: Nearly four years on the DaVita board.
- Standard terms: Compensation follows the non-employee director program described in the March 19, 2026 proxy; an indemnification agreement will be executed.
- No financial impact: The 8-K contains no earnings, guidance, or transaction disclosures; the press release is furnished under Item 7.01 and not deemed filed.
03—Questions
Frequently Asked Questions
Who is Pascal Desroches and why is he joining GE HealthCare's board?
Desroches is Senior Executive Vice President and CFO of AT&T, a role he has held since 2021. GE HealthCare cites his experience in finance, governance, large-scale technology, corporate strategy, capital deployment, and investor engagement as strengthening the Board as it executes its precision care and innovation strategy.
Why does the appointment take effect in January 2027 rather than immediately?
The filing does not explain the timing in detail. However, Desroches plans to retire from AT&T on December 31, 2026, so the January 4, 2027 start date appears to follow his departure from his current executive role.
Will his appointment affect GE HealthCare's financial results or guidance?
No. The 8-K contains no financial results, guidance, or transaction information. The appointment is a governance action, and its impact on the company's financial performance is not disclosed or expected in the filing.
Does his Audit Committee seat matter to investors?
It can be meaningful. Desroches has a background in KPMG, the SEC, and CFO roles, and he currently chairs the audit committee at Honeywell Aerospace. This experience may add financial reporting and internal control expertise to GE HealthCare's audit oversight, though the filing itself does not comment on his qualifications as a financial expert for SEC purposes.
Are there any conflicts of interest or related-party concerns?
The filing states there are no arrangements or understandings under which he was selected as a director and no transactions with the company that require disclosure under Item 404(a) of Regulation S-K. An indemnification agreement will be entered into, consistent with the company's standard practice for directors.
04—Continue